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Determining the etiology of sudden cardiac arrest or peri-arrest (sCA) without 
significant coronary artery disease (CAD) is crucial for management and 
prognosis.  Cardiovascular magnetic resonance (CMR) can detect morphological, 
functional or tissue abnormalities, and we sought to evaluate the role of CMR in 
determining sCA etiology and prognosis in survivors. 
  
Methods and Results:  
We retrospectively reviewed cardiac investigations and clinical outcomes in 
consecutive survivors of potentially fatal arrhythmias without CAD admitted to our 
institutions from 2008-2014. Following coronary angiography and echocardiography, 
all underwent CMR and, where indicated, electrophysiology studies. Major adverse 
cardiac events (MACE), comprising significant non-fatal ventricular arrhythmia or 
death, was the primary outcome.  
Of 164 included subjects (65% male, mean age 48 (18-80) years), CMR contributed 
to the diagnosis in 80 (49%) and was decisive in 50 cases (30%). Dilated 
cardiomyopathy (n=27), myocarditis or sarcoidosis (n=22), occult myocardial 
infarction (n=13) and hypertrophic cardiomyopathy (n=9) were most frequent. 
Arrhythmic causes were found in 14%, while no cause was identified in 36%. 
MACE occurred in 31% of subjects over a median follow-up of 32 months. MACE 
associated with presence of a CMR diagnosis, extent of late gadolinium 
enhancement (LGE), left and right ventricular ejection fraction (LVEF, RVEF). RVEF 




CMR identified a likely etiology for sCA in nearly half of survivors in whom CAD had 
been excluded. One in three subjects had MACE; risk doubled in those with a CMR 
diagnosis and some CMR parameters – LGE, LVEF and especially RVEF – 
associated with prognosis.  
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Surviving sudden cardiac arrest or a peri-arrest event (sCA) is increasingly likely in 
societies investing in emergency response capabilities1. In the absence of coronary 
artery disease (CAD), determining the etiology of sCA is often challenging 2-5.  
Although most sCA survivors receive implantable cardiac defibrillators (ICDs), other 
aspects of their management and prognosis will depend on the underlying cause. 
Additionally, although recurrent arrhythmia rates are high following the index sCA, 
some causes of sCA may be transient and only temporary secondary arrhythmia 
prevention may be needed – as indicated in the case of cardiac arrest immediately 
following an acute myocardial infarction6. Finally, inherited cardiac conditions are 
frequently identified as causes of sCA and an accurate diagnosis is essential for 
genetic testing and for family counselling and screening7,8. 
Notably, most studies of sCA include patients both with and without coronary artery 
disease.  In those excluding coronary disease, the majority are post-mortem studies 
in non-survivors2,9,10 or focus only on the young and/or athletes. For example, 
diagnoses based on electrophysiology studies (EPS) and dynamic ECG changes can 
be missed11, as well as those sensitive to sampling errors12. 
Cardiovascular magnetic resonance (CMR) can detect subtle structural, functional 
and tissue abnormalities of the cardiac muscle; in combination with other 
assessments, CMR can increase our ability to diagnose many of diseases affecting 
the heart muscle that are most commonly associated with sCA13,14. Alongside, late 
gadolinium enhancement (LGE) (both the presence and extent) has been found to be 
prognostic across a variety of cardiac diagnoses 15-18 and clinical settings, including 
cardiac arrest survivors13. 
CMR is therefore likely to have an additional role in determining the substrate for the 
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ventricular arrhythmias in sCA survivors, and for identifying those patients at greatest 
risk of recurrent arrhythmias 14,19,20. 
Our aims were therefore to: 
1. Provide a contemporary description of the non-coronary causes of sCA, their 
relative frequency in an adult population and estimate the frequency with which this 
carries implications for patient and family management. 
2. Describe the diagnostic utility of a clinical strategy based on CMR for the 
evaluation of adult sCA survivors without coronary disease. 
3. Assess the prognostic utility of CMR findings (LGE in particular) in this population 





The data that support the findings of this study are available from the corresponding 
authors upon reasonable request.  
 
Study population 
We retrospectively studied consecutive patients admitted at the London Chest and 
University College London Hospitals NHS Trusts between 2008 and 2014 (now part 
of Barts Heart Centre, Barts Health NHS Trust), who survived a resuscitated cardiac 
arrest, or sustained ventricular tachycardia with hemodynamic instability requiring 
emergent cardioversion (a peri-arrest scenario), between 2008 and 2014. All subjects 
underwent coronary angiography and those without significant coronary artery 
disease (luminal obstruction < 30%) and that underwent CMR were included in this 
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study. If an underlying cause was not identified from the CMR or if the ECG raised 
concern regarding a primarily arrhythmic cause, electrophysiology (EP) assessment 
was made - including ECG analysis, sodium channel blockade, catecholamine 
infusion, treadmill test and/or EPS, where deemed clinically indicated. 
The final clinical diagnosis for the etiology of the sCA was made during the index 
admission by the cardiology team managing the patient, using all available data 
(clinical, imaging and electrophysiological). 
 
Consent and Ethical Approval: This study was conducted as audit (Clinical 
Management of the Inherited and Acquired Heart Muscle Diseases, Barts Health 
NHS Trust audit No. 5298). All clinical data were collected as part of standard care 
and all patient identifiable fields were removed prior to analysis.  
 
CMR protocol 
All CMR studies were undertaken during the index admission following cardiac 
arrest. Scanning was performed on Philips® and Siemens® 1,5 Tesla scanners. All 
protocols included cine imaging and late gadolinium enhancement imaging. T1-
weighted imaging pre and post contrast and T2-weighted triple inversion recovery 
images (STIR) were acquired where deemed clinically indicated.  
LV dimensions, mass and systolic function were assessed using steady-state free 
precession (SSFP) cine imaging. Late gadolinium enhancement images were 
acquired 10 minutes post injection of 0.1mmol/Kg gadoterate meglumine (Dotarem® 
Guerbet S.A. France) with an inversion-recovery segmented gradient echo (Turbo-
Flash) sequence, with slice orientations corresponding to the cine images. In patients 
with limited breath holding ability or frequent ectopy, a single-shot SSFP-based 
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inversion recovery sequence was used.  
A quantitative evaluation of edema was obtained from T2-weighted short-tau 
inversion-recovery (T2w) images, by measurement of myocardial signal intensity 
normalized to skeletal muscle in the same slice21.  
Quantitative evaluation of the early gadolinium enhancement ratio (EGEr), a marker 
of hyperemia, analyzed from T1-weighted spin echo images, was obtained by 
measuring the signal intensity before and after contrast administration and 
normalized to the skeletal muscle21.   
All studies were analyzed by two investigators blinded to the original CMR results, 
final clinical diagnosis and outcomes, in a central core laboratory using CVI42 ® 
software (Circle Cardiovascular Imaging, Calgary, AB, Canada).  Standard volumetric 
analysis was performed (papillary muscles included as myocardium), and 
measurements indexed to body surface area. Late gadolinium enhancement was 
automatically quantified using a threshold of 5 standard deviations above the mean 
signal intensity of the remote myocardium22.  The site of enhancement was classified 
as subendocardial/ transmural (ischemic), or as epicardial/ midwall/ patchy (non 
ischemic). Very small or poorly defined patches of LGE (≤1% of total myocardium) 
were considered non specific. 
Final CMR diagnosis was obtained by consensus between at least two investigators. 
We followed the current criteria for defining ARVD23, DCM24, HCM25 and 
myocarditis21, as published elsewhere. 
 
Final clinical diagnosis 
We defined “final clinical diagnosis” as the cause of the sCA deemed responsible for 
the episode adjudicated by the medical team treating the patient, based on all clinical 
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information available (imaging, electrophysiological, biopsy, genetic). This did not 
need to coincide with the final CMR diagnosis. 
 
Outcome assessment 
The primary endpoint was the occurrence of major adverse cardiac events (MACE), 
defined as a composite of significant non-fatal ventricular arrhythmia (appropriate 
anti-tachycardia pacing or ICD shock, sustained ventricular tachycardia [VT] or 
ventricular fibrillation [VF]) and death.  
Clinical outcome information was obtained from electronic health records (EHR), with 
mortality data from linked national databases including NHS Spine. Follow-up 
arrhythmia data was obtained from implantable cardiac defibrillator (ICD) 
interrogation and from medical records.  
  
Statistical analyses 
Continuous data are described as mean ± standard deviation or median (25-75 
interquartile range) for non-gaussian distributions. Shapiro-Wilk test was used to 
assess normality. Categorical data are presented as absolute frequencies (n) and 
percentages.  
Baseline differences between patients with and without MACE were assessed, using 
univariable Cox regression analysis.  
The hazard ratio for the prediction of the events was calculated for MACE using Cox 
regression models. Multivariable analysis was performed using Cox regression with a 
stepwise forward selection method. Parameters that were significantly associated 
with MACE in the univariable analysis (p<0.1) and without collinearity were 
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considered.  Gender and age were also included because of their known clinical 
significance and impact on survival.  
Survival analysis was completed with event curves, described according to the 
Kaplan-Meier method, and comparison of event rates was performed using the log-
rank test. 
We used SPSS® software (version 20) for statistical analyses, considering 2-sided 




We included 164 patients, 65% (107) were male, with a mean age at presentation of 
48 ± 15 years (range 18 – 80 years). Baseline characteristics are presented in Table 
1; 9 patients had an arrest with a non-shockable rhythm (pulseless electric activity or 
asystole), 20 had sustained VT with hemodynamic instability (a peri-arrest scenario), 
and the remaining 135 had pulseless VT or VF. 
An implantable cardiac defibrillator (ICD) was placed in 70% (n=114). Follow-up data 
was available in all but one of the subjects. 
 
CMR findings and diagnoses 
The main parameters analyzed in CMR imaging are described in Table 2.   
Indexed cardiac volumes were normal in 71% of subjects and median LVEF was 59 
(IQR 47-68), with 31.7% of the subjects presenting LVEF≤50% (17.7% had LVEF 40-
50%; 7.3% had LVEF 30-40% and 6.7% had LVEF≤30%).  
 
Tissue characterization with late gadolinium enhancement:  
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Abnormal late gadolinium enhancement was detected in 61 (37%) of subjects – of 
these, it was predominantly subendocardial or transmural in 34% (n=21), midwall in 
13% (n=8), subepicardial in 33% (n=20), in a diffuse discontinuous distribution in 
11% (n=7) and 5 patients (8%) had more than one of these patterns. In almost all 
(n=54) of these subjects CMR provided a final diagnosis.  
There was no late gadolinium enhancement in 81 patients (49%). In the remaining 22 
patients (13%), subtle and/or non-specific LGE findings were present. 
 
Tissue characterization with T2-weighted imaging:  
T2-STIR imaging was available in 80 patients (49%). On visual assessment, there 
was evidence of myocardial edema (increased signal intensity in STIR images) in 
only 10 (6%) of the subjects – in 6 cases, this co-localized with LGE in a non-
ischemic pattern, in 2 with myocardial infarct (MI) pattern and the remaining 2 had no 
LGE. In 13% (n=22) of subjects, the calculated ratio of STIR signal intensity 
normalized to skeletal muscle was ≥ 2.   
 
Imaging-derived diagnosis: 
In 80 cases (49%), CMR findings contributed to determining the underlying etiology 
for the sCA (Table 3). The most frequent diagnoses made from CMR were dilated 
cardiomyopathy in 27 cases (17%), myocarditis or cardiac sarcoidosis in 22 (13%; 7 
of those with possible sarcoidosis), occult myocardial infarction in 13 (8%) and 
hypertrophic cardiomyopathy in 9 (6%).  
Minor and nonspecific changes not suggestive of a specific diagnosis were found in 
30 CMR scans (18% of the total, 35% of those without a diagnosis) and 55 patients 
(34%) patients had a completely normal scan. 
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In order to assess the incremental diagnostic value of CMR, a cardiologist performed 
an adjudicated review of the clinical history and of the exams, blinded to CMR 
findings and final diagnosis by the medical team.  
There were 50 patients in whom the final clinical diagnosis would not have been 
made without the additional morphological information and tissue characterization 
derived from the CMR scan.  These included myocarditis (n=14), sarcoidosis (n=7), 
occult myocardial infarction (n=12), arrhythmogenic right ventricular dysplasia (n=3), 
non-ischemic dilated cardiomyopathy (n=11 cases where CMR was required to 
exclude alternative differential diagnoses) and 3 other cases where the final clinical 
diagnoses required exclusion of other CMR-detectable pathology. 
It was also judged to be very relevant to support other diagnosis, for example 
hypertrophic cardiomyopathy (HCM).  
 
Electrophysiology findings and diagnoses 
An arrhythmic pathology was found in 26 cases and deemed to be the main cause 
for the sCA in 23 cases (14%): 13 patients had a channelopathy, 5 an accessory 
pathway and 5 an acquired arrhythmia with a reversible cause.  
 
Final clinical diagnosis 
After combining all clinical, imaging and EP findings, the most frequent final 
diagnoses made by the physicians were: dilated cardiomyopathy, myocarditis and 
prior myocardial infarction (Table 3). In 59 cases (36%), the clinicians felt that a 
specific diagnosis could not be determined; 41% of these were presumed to be 
idiopathic VT/VF according to the medical records. In 12 patients, more than one 
cause for the sCA was found, but one was felt to be predominant and was 
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considered the final diagnosis (Table 3). 
 
Follow-up - patient outcomes 
Over a median follow-up of 32 months (interquartile range 17-52), MACE occurred in 
51 patients (31%). In 47 patients (27%), a significant non-fatal ventricular arrhythmic 
event was recorded. A total of 9 patients (5.2%) died; 2 did not have an ICD – 
unfortunately we could not adjudicate the cause of death based on the available 
data. In 5 cases with ICD, a significant arrhythmic event had already been treated by 
the device before their death. 
An ICD complication was registered in 15 patients during follow-up (infection in 1, 
extrusion in 2, inappropriate shocks in 4 and lead displacement in 7 patients; 1 
patient had infection, extrusion and inappropriate shocks). Notably, the 50 patients 
without an ICD had fewer registered major adverse cardiac events (MACE) - 8% vs 
41%, p=0.008 (Cox regression). Most cases who did not get an ICD were driven by a 
conclusion that the underlying cause had resolved or could be managed with 
appropriate medication, or due to patient refusal or loss of follow-up. The final 
diagnosis and extension of LGE were not significantly different, but LVEF was higher 
(58% vs 56%, p= 0.041) and the presence of LGE was less common (24% vs 44%; 
p=0.022) in patients without an ICD. As far as we could determine, none of the 
patients included was totally dependent or in a vegetative state at the time of 





There was no statistically significant relationship between MACE and baseline 
demographic characteristics, conventional cardiovascular risk factors or clinical 
features of the SCA peri-arrest (Table 1). 
MACE were seen in 41% of the 80 patients with a CMR diagnosis, in 13% of the 23 
with a predominant EP diagnosis and in 25% of the 59 with “idiopathic” sCA. 
There was a non-significant trend towards lower MACE in the group with “idiopathic” 
sCA compared with those with a final etiologic diagnosis (24% versus 34%; 
p=0.338).  
Having a CMR-defined diagnosis was significantly associated with more MACE (41% 
vs 21%; p=0.022) and a shorter event-free survival – Figure 1. Considering the most 
common diagnoses, MACE occurred in 41% of patients with dilated cardiomyopathy 
and in 43% of those with myocarditis/sarcoidosis (50% of patients with myocarditis 
and 29% of those with sarcoidosis), 50% of those with missed MI and 38% with HCM 
(Table 2). In the 24 patients with an arrhythmic etiology there was significantly lower 
MACE when compared to all other patients (13% vs 34%; p=0.034). 
We did not find a statistically significant association between individual diagnoses 
and prognosis.  
In the cohort as a whole, several CMR parameters were associated with MACE in the 
univariable analysis (Table 2). These included the presence and extent of LGE 
(Figure 2), LV and RV ejection fraction (Supplementary Figures 1 and 2), left and 
right atrial area and ventricular volumes.  
The pattern of LGE (ischemic versus non ischemic) was not significantly related to 
the occurrence of MACE. 
Two methods of multivariable analysis for predicting MACE were considered. 
Covariates included LVEF, RVEF and LGE, all significantly associated with MACE in 
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the univariable analysis. Ventricular volumes were not included in the model (to avoid 
collinearity, since EF was included and derives from end-diastolic and end-systolic 
left ventricular volumes). A significant interaction between LVEF and RVEF in 
predicting MACE was excluded. We also included age and gender in the model 
(Methods section). We tested two models, using LGE as either a binary (clearly 
present or absent) or a continuous variable (% of myocardial mass). 
RVEF was independently associated with MACE in both models (Supplementary 
Tables 1 and 2).  
MACE rates were similar in patients with subtle/non-specific changes and those with 
a totally normal scan (respectively 20% and 22%). This lack of association between 
outcome and non-specific CMR changes remained when cases diagnosed with a 
primary arrhythmic cause were excluded (21% versus 25%; p=0.769) and when 




To date, this is the largest published cohort of cardiac arrest survivors in whom 
coronary disease had been excluded as the cause by coronary angiogram. By 
incorporating CMR into the diagnostic algorithm for investigation of sCA, the etiology 
was determined in nearly two thirds of patients, with the most common causes in this 
cohort being non-ischemic dilated cardiomyopathy, myocarditis and missed 
myocardial infarction. The prognosis following sCA however remains poor, with 
MACE in almost one in three within a median follow-up of less than 3 years, despite 
defibrillator implantation in 70%.  Those with a CMR-defined diagnosis had especially 
high MACE rates, with the presence of LGE and particularly RVEF as independent 
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predictors of future events.  
Worldwide, coronary artery disease is the leading cause for sCA26, hence coronary 
angiography is frequently recommended, particularly if an acute coronary syndrome 
is suspected27,28.  CMR is not specifically recommended in recent cardiac arrest 
guidelines, although the indication for a thorough investigation to find an etiology was 
reinforced27,28. 
Previous studies investigating causes of sCA (without systematic use of CMR) have 
mainly focused on manifestations of coronary artery disease29. Dilated 
cardiomyopathy has been the second most frequent cause of sCA observed in 
adults4. The few studies that extensively explore the non-ischemic causes of sCA are 
mainly in children or young athletes, with hypertrophic cardiomyopathy/ left 
ventricular hypertrophy usually the most common etiology, while myocarditis and 
congenital coronary abnormalities are more common than in older cohorts10,30. In 
those studies, most of them post mortem, between 5 to 18% of the cases had no 
identifiable etiology 2,10,30-32, reaching around a third of the patients in studies with 
survivors13,14.  This often leaves patients, their families and clinicians with significant 
uncertainty regarding clinical management. A diagnostic approach with routine use of 
CMR and upstream angiography appears to be a successful method for determining 
the etiology, with CMR alone providing a cause in nearly half of patients. The 
relatively unique ability of CMR to perform tissue characterization allows detection of 
myocardial edema and focal scar, enabling identification of many conditions that are 
difficult to diagnose using other modalities.  Our results show that CMR, being able to 
give information about RVEF and LGE, offers additional prognostic value compared 
to echocardiographic findings.  
CMR was crucial for the main final clinical diagnosis in 50 cases (30%), while it gave 
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an important contribution to all the other cases where it was diagnostic. Cases of 
myocardial inflammation and specially ‘occult’ MI would not have been detected 
without CMR’s tissue characterization. CMR was also pivotal in the diagnosis of 
ARVD. In fact, CMR can help confirm a diagnosis, suggest a hitherto unexpected 
diagnosis and contribute to eliminate differential diagnoses. 
These data also highlight the wide range of potential causative underlying diseases 
in sudden cardiac arrest or peri-arrest cases, and illustrate the importance of 
identifying a diagnosis to facilitate treatment, prognosis and family screening. Despite 
all subjects having undergone coronary angiography and echocardiography, the 
frequency of occult infarcts was high; CMR provides a sensitive method for detection 
and enables administration of appropriate secondary preventative therapies. A recent 
study of 137 cardiac arrest survivors13 without a clear diagnosis before performing 
CMR reported a higher prevalence of myocardial infarction (58% of patients), 
possibly related to the application of different angiographic criteria for inclusion (we 
excluded coronary disease with any stenosis >30%).  
From our data, over one in four subjects were diagnosed with a potential inherited 
condition and one in five had an acquired cause, thereby facilitating targeted family 
screening and genetic testing.  This not only helps to diagnose subclinical conditions 
in family members, but also to alleviate concern in family members of those with non-
inherited conditions.   
Patients with an identified etiology for their sCA had a worse prognosis than those 
labelled as ‘idiopathic VF’, with higher event rates in those with structural or 
functional cardiac abnormalities identified by CMR. Similar to studies of specific 
cardiomyopathies, the presence of LGE, lower LVEF and RVEF were associated with 
shorter event-free survival. LGE extent was not prognostic in this cohort, although 
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this may be because of study power or the method for scar quantification used 
22,33,34.  
However, over a third of the cohort received no etiological cardiac diagnosis, and 
these patients remain a difficult group to manage clinically, particularly given the high 
MACE rates of one in four. In other studies with sCA survivors the percentages of 
cases without a final determined etiology are identical to ours13,14. Therefore, given 
the high recurrence of events and lack of ability to identify truly low-risk patients, ICD 
implantation must always be considered in these patients.  
Our data also demonstrate that cardiac arrest and resuscitation do not necessarily 
produce detectable changes by CMR. This means that if changes are seen in a CMR 
scan in this context, we cannot assume that they are solely due to consequences of 
the arrest per se. However, subtle non-specific CMR abnormalities did not influence 
prognosis. 
 
Limitations and strengths 
This is a retrospective study that used a relatively standardized approach to survivors 
of cardiac arrests and CMR exams were blindly reviewed by at least two observers.  
Given the design of the study, we can only derive association between the CMR 
findings and sCA; causality can only be hypothesized.  
Non-survivors were not included and diseases with a more malignant course may 
therefore be under-represented. Patients with a presumed coronary etiology for their 
arrests were excluded and this may have included patients with dual pathology or 
bystander coronary disease. Patients who could not undergo CMR because of 
hemodynamic instability, functional deficits that precluded breath-holding, severe 
renal failure, claustrophobia or magnetic devices were also excluded. 
 18 
Validation of CMR tissue characterization is currently incomplete. Notably, 
endomyocardial biopsy was not performed as a component of this clinical pathway 
and might have added valuable additional information.  
The cohort size prevents more detailed study of etiologic subgroups and we must be 
cautious in interpreting the prognostic value of individual CMR parameters (including 
EF and LGE) without first considering them within a diagnostic framework.  
Finally, we analyzed all-cause mortality rather than cardiovascular death, since the 




By incorporating CMR in clinical pathway for investigation of sudden cardiac arrest in 
the absence of CAD, a cause can be identified in nearly two thirds of patients.  Many 
of the most frequent etiologies identified using CMR (idiopathic dilated 
cardiomyopathy, myocarditis and occult myocardial infarction) have important 
implications with regard to specific clinical management, family screening and 
prognosis.  Although the risk of recurrent ventricular arrhythmias and death is high 
across this patient population, patients diagnosed with a structural or functional 
cardiac abnormality by CMR had a two-fold increased risk.  LGE and biventricular 
systolic function were associated with prognosis, with RVEF being an independent 
predictor. We therefore advocate consideration of CMR for investigation and 
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Figure 1 - Kaplan-Meier curves displaying the event-free survival according to the 
findings in CMR: patients with a CMR-defined diagnosis had a worse prognosis than 
those with a normal scan or one with minor nonspecific changes (p=0.018 in the Log-
rank test; HR=2, CI 95%= 1.1-3.5). 
 
 
Figure 2 - Kaplan-Meier curves of the MACE-free survival according to the presence 
of LGE (late gadolinium enhancement), which showed a significant relationship (Log-















Table 1 - Patients’ characteristics according to the occurrence of MACE during 
follow-up.  
 








Age (median (IQR); years) 48 (23) 47 (23) 52 (23) 0.100 
Gender (% male) 65.2 61.9 72.5 0.265 
Hypertension (n; %) 24 (15%) 13 (12%) 11 (22%) 0.100 
Diabetes mellitus (n; %) 5 (3%) 1 (0.9%) 4 (8%) 0.082 
Smoking history (n; %) 12 (7%) 10 (9%) 2 (4%) 0.595 
Dyslipidemia (n; %) 5 (3%) 3 (3%) 2 (4%) 0.157 
Obesity* (n; %) 3 (2%) 1 (0.9%) 2 (4%) 0.106 
Excessive alcohol intake (n; %) 9 (5%) 6 (5%) 3 (6%) 0.256 
Illicit drug use (n; %) 5 (3%) 5 (4%) 0 0.681 
Chemotherapy (n; %) 3 (2%) 3 (3%) 0 0.698 
Family history of SCD or IHD (n; %) 6 (4%) 5 (4%) 1 (2%) 0.727 
Autoimmune disease (n; %) 4 (2%) 4 (4%) 0 0.650 
OOHCA (n; %) 122 (74%) 86 (76%) 36 (71%) 0.226 
Time to return to spontaneous 
circulation (median (IQR); minutes) 
 
15 (10) 15 (10) 15 (24) 0.227 
Shockable rhythm identified by first 
responder (n; %) 
 
155 (94%) 105 (93%) 50 (98%) 0.241 
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Length of hospital admission 
(median (IQR); days) 
 
10 (10)  10 (12) 10 (5) 0.370 
 
Abbreviations: MACE – major adverse cardiac events (a composite of significant non-fatal 
arrhythmia and death); SCD – sudden cardiac death; IHD – ischemic heart disease; OOHCA 
– out of hospital cardiac arrest; VT – ventricular tachycardia. IQR – interquartile range 
(quartile 75 - quartile 25). SD – standard deviation.  




















Table 2 – CMR findings in the total sample and divided according to the 












LVEDV, indexed to BSA (mL/m2) 83 (31) 80 (28) 91 (45) 0.021 
LVESV, indexed to BSA (mL/m2) 33 (30) 30 (26) 42 (38) 0.002 
LV mass, indexed to BSA (g/m2) 70 (22) 69 (22) 75 (30) 0.276 
LVEF (%) 59 (21) 62 (19) 53 (23) 0.001 
LV RWMA (% of patients) 28 20 46 0.003 
Cardiac output (L/min) 5.9 (1.8) 6.0 (1.8) 5.6(1.9) 0.237 
Stroke volume, BSA-indexed (mL/m2) 46 (15) 48 (14) 44 (17) 0.115 
RVEDV, indexed to BSA (mL/m2) 81 (25) 77 (27) 83 (21) 0.029 
RVESV, indexed to BSA (mL/m2) 34 (18) 31 (16) 41 (17) 0.001 
RVEF (%) 57 (10) 59 (11) 54 (12) <0.001 
RV RWMA (% of patients) 6 4 11 0.735 
TAPSE (mm) 20 (8) 22 (7) 18 (7) 0.070 
Left atrial area (cm2) 21 (7) 21 (7) 24 (8) 0.002 
Right atrial area (cm2) 20 (8) 20 (7) 23 (9) <0.001 
Pericardial abnormalities (%of patients) 2 2 2 0.778 
Mean EGEr in T1 * 
1.0(0.01) 1.0 (0.01) 1.0 (0.3) 0.364 
T2 STIR (mean ratio) † 
2.0 (0.6) 2.0 (0.4) 2.3 (1.1) 0.128 
STIR visually abnormal (% of patients)‡ 
6 6 6 0.907 
LGE present (% of patients) 37 30 51 0.020 
LGE distribution (% of patients) 
   
0.064 
     -No LGE 49 55 38 
      -Subendocardial or transmural LGE 13 12 14 
      -Epicardial, midwall or patchy LGE 24 18 38 
      -Minor nonspecific LGE§ 
13 15 10 
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LGE quantification as % of LV mass  0.001 (4) 0.001 (3) 3.0 (11) 0.022 
 
Results are presented as median (interquartile range) or as a percentage. 
Abbreviations: CMR – cardiovascular magnetic resonance; MACE – major adverse cardiac 
events (potentially fatal arrhythmia or death); BSA – body surface area; LVEDV – left 
ventricular end diastolic volume; LVESV - left ventricular end systolic volume; LV mass – left 
ventricular mass; LV – left ventricle; LVEF – left ventricular ejection fraction (measured on 
short axis stack pictures; using the biplane method, on 4-chamber and 2-chamber views); 
RWMA – regional wall motion abnormalities; MAPSE - mitral annular plane systolic 
excursion; RVEDV – right ventricular end diastolic volume; RVESV - right ventricular end 
systolic volume; RVEF – right ventricular ejection fraction; RV – right ventricle; TAPSE – 
tricuspid annular plane systolic excursion; LGE – late gadolinium enhancement. 
* Early gadolinium enhancement ratio (EGEr) -  normalized to the skeletal muscle.  
† T2-weighted STIR (short tau inversion recovery) ratio of signal intensity normalized to 
skeletal muscle.  
‡ Increased signal intensity in STIR images clearly seen visually. 












Table 3 – Predominant diagnosis identified by CMR and final clinical diagnosis 













Unknown cause 84 (51%) 59 (36%) 14 (24%) 
DCM (“idiopathic”) 27 (17%) 22 (13%) 9 (41%) 
Myocarditis 
22 (13%) 
14 (9%) 7 (50%) 
Cardiac sarcoidosis 7 (4%) 2 (29%) 
IHD 13 (8%) 12 (7%) 6 (50%) 
Long QT syndrome  11 (7%) 1 (9%) 
HCM 9 (6%) 8 (5%) 3 (38%) 
Arrhythmia due to drugs or ionic 
disturbance 
 5 (3%) 0 
Accessory pathway with fast conduction  5 (3%) 0 
DCM due to cardiotoxic substance  4 (2%) 2 (50%) 
Severe valvular disease  4 (2%) 4 (2%) 1 (25%) 
ARVD 3 (2%) 3 (2%) 2 (67%) 
Probable coronary vasospasm  3 (2%) 1 (33%) 
Undetermined cardiomyopathy/ other 
cardiac disease 
1 (1%) 3 (2%) 1 (33%) 
Brugada syndrome  2 (1%) 2 (100%) 
Takotsubo cardiomyopathy 1 (1%) 1 (1%) 0 
Non-cardiac cause  1 (1%) 0 
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Note: In 12 patients, there were multiple diagnoses made, however all patients were given 
one final clinical diagnosis thought to be the main cause of the arrhythmic event.  
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